Evidence map›Paper›PMID 23496347›Full record

ReviewExpert opinion on pharmacotherapy2013

Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients.

Michelle C Janelsins, Mohamedtaki A Tejani, Charles Kamen, Anita R Peoples, Karen M Mustian, Gary R Morrow

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert opinion on pharmacotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Review
  16. Article
  17. Awareness of chemotherapy-induced nausea and vomiting and adherence to guidelines: results of a multinational and multicenter survey, part of the THRIVE program.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  18. Article
  19. Risk factors associated with anticipatory nausea and vomiting in children receiving chemotherapy: a cross-sectional study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  20. Review

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Michelle C JanelsinsUniversity of Rochester Medical Center, James P Wilmot Cancer Center, Department of Radiation Oncology, 265 Crittenden Blvd, Box 658, Rochester, NY 14642, USA.
Mohamedtaki A Tejani
Charles Kamen
Anita R Peoples
Karen M Mustian
Gary R Morrow

Funding

UNIVERSITY OF ROCHESTER--CCOP RESEARCH BASEU10CA037420 · NCI · UNIVERSITY OF ROCHESTER · PI MORROW, GARY R · 1985 to 2014
$21.1M
Cancer Control Research Training Curriculum (R25T)R25CA102618 · NCI · UNIVERSITY OF ROCHESTER · PI JANELSINS, MICHELLE C, MORROW, GARY R · 2004 to 2018
$6.7M
NCI NIH HHS R25 CA102618NCI NIH HHS U10 CA037420
6 · The paper itself

Abstract

introductionNausea and vomiting are two of the most frequent and troubling side effects patients experience during chemotherapy, interfering with compliance with cancer therapies and quality of life. While newly available treatments have improved our ability to manage nausea and vomiting, anticipatory and delayed nausea and vomiting are still major problems for patients receiving chemotherapy. Many cancer patients consider delaying future chemotherapy cycles and some contemplate stopping chemotherapy altogether because of their fear of experiencing further nausea and vomiting. AREAS COVERED: The purpose of this article is to provide an overview of the pathopsychophysiology of chemotherapy-induced nausea and vomiting (CINV), the recommended guidelines for treatment, and current agents in late-stage clinical trials, and future research needs to address the continued challenges of treatment-related nausea and vomiting. EXPERT OPINION: Despite advances in pharmaceutical and behavioral therapies, and the provision of standard clinical guidelines for effectively managing CINV, patients continue to experience it. Moreover, control of nausea, acute and delayed, and anticipatory nausea and vomiting remains an important, unmet need among cancer patients. It is critical to focus attention on better understanding the mechanisms underlying nausea, anticipatory symptoms and delayed symptoms.

Indexed as

AnimalsAntiemeticsAntineoplastic AgentsClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicDrug DesignHumansNauseaPractice Guidelines as TopicQuality of LifeVomitingAntiemeticsAntineoplastic Agents

Identifiers

PMID23496347
PMCPMC3938333

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.